Lesions L, Geyer FC, Pareja F, Weigelt B, Rakha E, Ellis IO, Schnitt SJ, Reis-Filho JS. The spectrum of triple-negative breast disease. Am J Pathol. 2017;187:2139–51.
Liu Z, Li M, Jiang Z. A comprehensive immunologic portrait of triple-negative breast cancer. Transl Oncol. 2018;11:311–29.
Article PubMed PubMed Central Google Scholar
Corti C, Giachetti PPMB, Eggermont AMM, Delaloge S, Curigliano G. Therapeutic vaccines for breast cancer: has the time finally come? Eur J Cancer. 2022;160:150–74.
Article CAS PubMed Google Scholar
Katz H, Alsharedi M. Immunotherapy in triple-negative breast cancer. Med Oncol. 2018;35:1–9.
Abdou Y, Goudarzi A, Yu JX, Upadhaya S, Vincent B, Carey LA. Immunotherapy in triple negative breast cancer: beyond checkpoint inhibitors. Npj Breast Cancer. 2022;8(1):121.
Article CAS PubMed PubMed Central Google Scholar
Li L, Zhang F, Liu Z, Fan Z. Immunotherapy for triple-negative breast cancer: combination strategies to improve outcome. Cancers. 2023;15(1):321.
Article CAS PubMed PubMed Central Google Scholar
Atapour A, Negahdaripour M, Ghasemi Y, Razmjuee D, Savardashtaki A, Mousavi SM, Hashemi SA, Aliabadi A, Nezafat N. In silico designing a candidate vaccine against breast cancer. Int J Pept Res Ther. 2020;26:369–80.
Li W, Joshi MD, Singhania S, Ramsey KH, Murthy AK. Peptide vaccine: progress and challenges. Vaccines. 2014;2:515–36.
Article CAS PubMed PubMed Central Google Scholar
Chun S, Muthu M, Gopal J, Paul D, Kim DH, Gansukh E, Anthonydhason V. The unequivocal preponderance of biocomputation in clinical virology. RSC Adv. 2018;8:17334–45.
Article CAS PubMed PubMed Central Google Scholar
Liu CC, Yang H, Zhang R, Zhao JJ, Hao DJ. Tumour-associated antigens and their anti-cancer applications. Eur J Cancer Care. 2017;26(5):e12446.
Mahdevar E, Safavi A, Abiri A, Kefayat A, Hejazi SH, Miresmaeili SM, Iranpur MV. Exploring the cancer-testis antigen BORIS to design a novel multi-epitope vaccine against breast cancer based on immunoinformatics approaches. J Biomol Struct Dyn. 2022;40:6363–80.
Article CAS PubMed Google Scholar
Parvizpour S, Razmara J, Pourseif MM, Omidi Y. In silico design of a triple-negative breast cancer vaccine by targeting cancer testis antigens. BioImpacts. 2019;9:45–56.
Article CAS PubMed Google Scholar
Nandini H, Krishnamoorthy R, Karuppasamy R. Designing a novel SOX9 based multi-epitope vaccine to combat metastatic triple-negative breast cancer using immunoinformatics approach. Mol Divers. 2022. https://doi.org/10.1007/s11030-022-10539-w.
Anderson GS, Ballester-Beltran J, Giotopoulos G, Guerrero JA, Surget S, Williamson JC, So T, Bloxham D, Aubareda A, Asby R, Walker I. Unbiased cell surface proteomics identifies SEMA4A as an effective immunotherapy target for myeloma. Am J Hematol. 2022;139:2471–82.
Suga Y, Nagatomo I, Kinehara Y, Koyama S, Okuzaki D, Osa A, Naito Y, Takamatsu H, Nishide M, Nojima S, Ito D. IL-33 induces sema4a expression in dendritic cells and exerts antitumor immunity. J Immunol. 2021;207:1456–67.
Article CAS PubMed Google Scholar
Jiang J, Zhang F, Wan Y, Fang K, Yan ZD, Ren XL, Zhang R. Semaphorins as potential immune therapeutic targets for cancer. Front Oncol. 2022;12:48.
Gao C, Wang L, Zhao W, Zhang B, Zhang J. The expression and clinical significance of sema4a in triple negative breast cancer. J Clin Nurs Res. 2019;4:4–7.
Liu X, Sun Y, Tian W, Wang F, Lv X, Wang M, Sun T, Zhang J, Wang L, Han M. SEMA4A responds to hypoxia and is involved in breast cancer progression. Biol Pharm Bull. 2018;41:1791–6.
Article CAS PubMed Google Scholar
Bairoch A, Apweiler R, Wu CH, Barker WC, Boeckmann B, Ferro S, Gasteiger E, Huang H, Lopez R, Magrane M, Martin MJ. The universal protein resource (UniProt). Nucleic Acids Res. 2005;33:154–9.
Jurtz V, Paul S, Andreatta M, Marcatili P, Peters B, Nielsen M. NetMHCpan-4.0: improved peptide–MHC class I interaction predictions integrating eluted ligand and peptide binding affinity data. J Immunol. 2017;199(9):3360–8.
Article CAS PubMed Google Scholar
Reynisson B, Barra C, Kaabinejadian S, Hildebrand WH, Peters B, Nielsen M. Improved prediction of MHC II antigen presentation through integration and motif deconvolution of mass spectrometry MHC eluted ligand data. J Proteome Res. 2020;19:2304–15.
Article CAS PubMed Google Scholar
Saha S, Raghava GPS. Prediction methods for B-cell epitopes. Methods Mol Biol. 2007;409:387–94.
Article CAS PubMed Google Scholar
Ponomarenko J, Bui HH, Li W, Fusseder N, Bourne PE, Sette A, Peters B. ElliPro: a new structure-based tool for the prediction of antibody epitopes. BMC Bioinform. 2008;9:1–8.
Doytchinova IA, Flower DR. VaxiJen: a server for prediction of protective antigens, tumour antigens and subunit vaccines. BMC Bioinform. 2007;8:1–7.
Dhanda SK, Vir P, Raghava GP. Designing of interferon-gamma inducing MHC class-II binders. Biol Direct. 2013;8(1):1–5.
Gupta S, Kapoor P, Chaudhary K, Gautam A, Kumar R, Raghava GPS. In silico approach for predicting toxicity of peptides and proteins. PLoS ONE. 2013. https://doi.org/10.1371/journal.pone.0073957.
Article PubMed PubMed Central Google Scholar
Dimitrov I, Bangov I, Flower DR, Doytchinova I. AllerTOP vol 2—a server for in silico prediction of allergens. J Mol Model. 2014. https://doi.org/10.1007/s00894-014-2278-5.
Calis JJ, Maybeno M, Greenbaum JA, Weiskopf D, De Silva AD, Sette A, Keşmir C, Peters B. Properties of MHC class I presented peptides that enhance immunogenicity. PLoS Comput Biol. 2013. https://doi.org/10.1371/journal.pcbi.1003266.
Article PubMed PubMed Central Google Scholar
Dariushnejad H, Ghorbanzadeh V, Akbari S, Hashemzadeh P. Design of a novel recombinant multi-epitope vaccine against triple-negative breast cancer. Iran Biomed J. 2022;26:160–74.
PubMed PubMed Central Google Scholar
Gasteiger E, Hoogland C, Gattiker A, Wilkins MR, Appel RD, Bairoch A. Protein identification and analysis tools on the ExPASy server. Proteomics Protoco Handbook. 2005. https://doi.org/10.1385/1-59259-890-0:571.
Bui HH, Sidney J, Dinh K, Southwood S, Newman MJ, Sette A. Predicting population coverage of T-cell epitope-based diagnostics and vaccines. BMC Bioinform. 2006;7(1):153.
Jones DT. Protein secondary structure prediction based on position-specific scoring matrices. J Mol Biol. 1999;292:195–202.
Article CAS PubMed Google Scholar
Kim DE, Chivian D, Baker D. Protein structure prediction and analysis using the Robetta server. Nucleic Acids Res. 2004;32:526–31.
Laskowski RA, MacArthur MW, Moss DS, Thornton JM. PROCHECK: a program to check the stereochemical quality of protein structures. J Appl Crystallogr. 1993;26:283–91.
Colovos C, Yeates TO. Verification of protein structures: patterns of nonbonded atomic interactions. Protein Sci. 1993;2:1511–9.
Article CAS PubMed PubMed Central Google Scholar
Luthy R, Bowei J, Einsenberg D. Verify3D: assessment of protein models with three-dimensional profiles. Methods Enzymol. 1997;277:396–404.
Wiederstein M, Sippl MJ. ProSA-web: interactive web service for the recognition of errors in three-dimensional structures of proteins. Nucleic Acids Res. 2007;35:407–10.
Kozakov D, Hall DR, Xia B, Porter KA, Padhorny D, Yueh C, Beglov D, Vajda S. The cluspro web server for protein-protein docking. Nat Protoc. 2017;12:255–78.
Article CAS PubMed PubMed Central Google Scholar
Al-Muhanna S, Al-Muhanna A. Construction and transformation of recombinant pet28a expression vector in bl21 (de3) cells with basic bioinformatics analysis. Biochem Cell Arch. 2018;18(1):147–52.
Rapin N, Lund O, Bernaschi M, Castiglione F. Computational immunology meets bioinformatics: the use of prediction tools for molecular binding in the simulation of the immune system. PLoS ONE. 2010;5(4):e9862.
Article PubMed PubMed Central Google Scholar
Kessler JH, Melief CJM. Identification of T-cell epitopes for cancer immunotherapy. Leukemia. 2007;21:1859–74.
留言 (0)